For patients with advanced nonsquamous non‐small cell lung cancer (NSCLC), immunotherapy or antiangiogenic therapy combined with pemetrexed and cisplatin/carboplatin have both shown significant efficacy at programmed cell death ligand 1 (PD‐L1) levels of <1%. Here, CD274 is linked to non-small cell lung carcinoma.